The variable manifestations of disease in pyruvate kinase deficiency and their management

Hanny Al-Samkari, Eduard J. van Beers, Kevin H.M. Kuo, Wilma Barcellini, Paola Bianchi, Andreas B. Glenthøj, María Mañú-Pereira, Richard van Wijk, Bertil Glader, and Rachael F. Grace

Disclosures: Al-Samkari: Consultancy (Agios, Dova, Moderna); Research Funding (Dova, Agios). Van Beers: Consultancy and Research Funding (Agios). Kuo: Honoraria (Alexion, Novartis); Consultancy (Agios, Alexion, Bluebirdbio, Celgene, Novartis, Pfizer); Data Safety Monitoring Board Chair (Bioverativ). Barcellini: Consultancy (Agios, Apellis, Alexion, Bioverativ, Novartis). Bianchi: Consultancy (Agios). Glenthøj: Consultancy (Agios, Celgene, Novartis, Novo Nordisk); Research Funding (Alexion). Mañú Pereira: Consultancy and Research Funding (Agios). Van Wijk: Consultancy and Research Funding (Agios). Glader: Scientific Advisor and Consultancy (Agios), Research Funding (Agios). Grace: Scientific Advisor and Consultancy (Agios), Research Funding (Agios, Novartis). The decision to write this manuscript was entirely that of the authors; additionally, no company or commercial interest had any input or influence of any kind on the contents of the manuscript.

Contributions: All of the authors contributed to writing the first draft of the manuscript, concept and design, development of recommendations, critical revision of the intellectual content, and final approval.